A 9-amino-acid pituitary hormone, FDA-approved as Pitocin for labor and postpartum bleeding; nasal sprays remain unproven.
Also called Pitocin, Syntocinon, OXT, Intranasal oxytocin
Oxytocin is a nine-amino-acid hormone made in the hypothalamus and released from the back of the pituitary gland. Its two best-understood jobs are squeezing the uterus during labor and pushing milk out of the breast during nursing. As the IV drug Pitocin it is one of the most used drugs in obstetrics: hospitals give it to start or strengthen labor and to stop bleeding after delivery.
The internet knows oxytocin as the 'love hormone' and sells it as a nasal spray for bonding, social anxiety, autism, sex and weight loss. That reputation comes from small lab studies from the 2000s that measured trust games or face reading after one spray. Larger, more careful trials have mostly come up empty: a 290-child autism trial found no benefit over placebo after 24 weeks, and an 8-week obesity trial found no weight loss. Researchers have also shown that only a tiny fraction of a nasal dose appears to reach the fluid around the brain.
As a hospital drug, oxytocin is powerful and closely monitored: too much can overstimulate the uterus and, because it acts a little like the water-retaining hormone vasopressin, can cause dangerously low sodium. The nasal sprays sold by compounding pharmacies are not FDA-approved products, and their doses and absorption have not been reviewed.
What it binds to, and what happens inside the body after that, step by step.
Oxytocin binds the oxytocin receptor, a G-protein-coupled receptor found on uterine muscle, breast milk-duct cells and in several brain regions. In the uterus it raises calcium inside muscle cells and triggers rhythmic contractions, and the uterus becomes far more sensitive to it late in pregnancy. Because it differs from vasopressin by only two amino acids, high doses also act like an antidiuretic and make the kidneys hold water.
Human results and animal results are kept apart below. A result in rats tells you a mechanism is plausible. It does not tell you what happens in a person.
For its approved hospital uses, oxytocin is backed by decades of use and very large trials, including a 29,645-woman trial against carbetocin for preventing bleeding after birth. For off-label nasal use the picture is weak: early social-behavior studies were small and likely overstated, the largest autism RCT was negative, an 8-week obesity RCT was negative, and a 2026 meta-analysis across mental disorders found no significant overall effect.
29,645 women giving birth vaginally in 10 countries
Blood loss of 500 mL or more, or need for more drugs, occurred in 14.4% with 10 IU oxytocin and 14.5% with carbetocin.
Read the study290 children and teens aged 3 to 17 with autism, 24 weeks
Social withdrawal scores improved by 3.7 points on oxytocin and 3.5 on placebo, a difference of 0.2 (P = 0.61).
Read the study61 adults with obesity (mean BMI 36.9), 8 weeks
Weight change was 0.20 kg on oxytocin vs 0.26 kg on placebo (P = 0.934); test-meal intake was about 152 kcal lower.
Read the study1,922 participants with autism, schizophrenia, substance use and other disorders
Overall effect was small and not significant (g = 0.17, 95% CI -0.05 to 0.38), with a small signal in schizophrenia (g = 0.12).
Read the study28 studies, 726 people with autism, including uncontrolled studies
Reported a benefit on social functioning but not on non-social symptoms; it pooled open-label studies and predates the negative SOARS-B trial.
Read the studyNo preclinical studies are listed as key studies here. The human data above carries the evidence.
These are questions the published research has not answered.
The Pitocin label carries an Important Notice that it is not indicated for elective induction of labor. It is given by IV infusion or IM injection in a hospital, and labor induction is IV only. Pitocin's current US application, NDA 018261, was approved in 1980. Outside the US the same injection is widely sold as Syntocinon. No intranasal oxytocin product is FDA-approved for any use. Carbetocin, a longer-acting oxytocin analogue, is approved in many countries but not the US. Oxytocin is not on the WADA Prohibited List.
How much of Oxytocin is left after a single dose
Simple first-order model from the published half-life. Real clearance varies with dose, route, kidney and liver function and formulation. This is not a dosing schedule.
This table records the doses that trials and approved labels used, with the source for each row. It is a record of research, not a recommendation, and it is open to free members.
Which symptoms are expected and which mean stop and get help: side effects and red flags.
Tap a claim to see what the studies found.
Early single-dose lab studies reported this, but a 2016 statistical review concluded the field is underpowered and that most published nasal oxytocin findings probably are not true effects.
The largest trial, 290 children over 24 weeks, found almost identical improvement on oxytocin and placebo (difference 0.2 points, P = 0.61).
In an 8-week randomized trial in 61 adults with obesity, weight change was 0.20 kg on oxytocin and 0.26 kg on placebo.
Only a very small amount appears in cerebrospinal fluid, while blood levels rise far above normal, so effects may come from the body rather than the brain.
It is released during birth, nursing and sex, and animal studies link it to pair bonding. In humans its proven, measurable job is uterine contraction and milk letdown; behavioral effects of giving it as a drug are unproven.
Pitocin is supplied as a 10 units/mL solution and stored at 20 to 25°C (68 to 77°F) per its label. There is no labeled guidance for research-grade powder.
Not applicable to Pitocin, which is a ready-made solution that hospital staff dilute into IV fluid (10 units in 1,000 mL for labor). No published stability data exist for compounded nasal sprays.
One email when a trial reads out, a label changes or the FDA acts on a peptide. Free, no selling of peptides, unsubscribe any time.